Axonal outgrowth is of paramount significance for establishing the intricate neuronal network both during embryogenesis and nerve regeneration. Vascular endothelial growth factor (VEGF), which is known for its essential role in vascular sprouting and its involvement in cancer, has recently been found to exert a trophic activity on neurons leading to an increased axonal outgrowth. Although two receptors, VEGFR-2 and neuropilin-1, were identified on neurons, the signaling pathways associated with them are not well understood. The aim of this study was to analyze the influence of VEGF on the growth cone morphology and motility of dorsal root ganglia (DRG) neurons. Moreover, we aimed for a deeper understanding of VEGFR-2 on growth cones that potentially mediates the stimulating and attractive effects. We cultivated chicken DRG in medium containing mouse VEGF and analyzed growth cone size. The data presented here show a positive effect of VEGF on growth cone size. Furthermore, we interrupted the activity of VEGFR-2 by either blocking the tyrosine residue 1214 (tyr1214) or by inhibiting the receptor phosphorylation with axitinib, a novel small molecule, which has recently entered phase III trials for cancer treatment. Disruption of the VEGFR-2 leads to a significantly diminished growth cone size. Based on these findings, we propose a positive effect of VEGF on peripheral nervous system growth cone size and show for the first time quantitative data to underline this hypothesis. Additionally, we propose that VEGFR-2 and especially the tyr1214-dependent pathway of VEGFR-2 are of importance in VEGF signaling in the growth cone of DRG neurons.

Keywords:
Signaling pathway, Dorsal root ganglia, Growth cone, Vascular endothelial growth factor, Vascular endothelial growth factor receptor 2, Axitinib
1.
Albuquerque, R.J., T. Hayashi, W.G. Cho, M.E. Kleinman, S. Dridi, A. Takeda, J.Z. Baffi, K. Yamada, H. Kaneko, M.G. Green, J. Chappell, J. Wilting, H.A. Weich, S. Yamagami, S. Amano, N. Mizuki, J.S. Alexander, M.L. Peterson, R.A. Brekken, M. Hirashima, S. Capoor, T. Usui, B.K. Ambati, J. Ambati (2009) Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth. Nat Med 15: 1023–1030.
2.
Argiro, V., M.B. Bunge, M.I. Johnson (1984) Correlation between growth form and movement and their dependence on neuronal age. J Neurosci 4: 3051–3062.
3.
Bradford, M.M. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248–252.
4.
Brockington, A., C. Lewis, S. Wharton, P.J. Shaw (2004) Vascular endothelial growth factor and the nervous system. Neuropathol Appl Neurobiol 30: 427–446.
5.
Bromberg, K.D., R. Iyengar, J.C. He (2008) Regulation of neurite outgrowth by Gi/o signalling pathways. Front Biosci 13: 4544–4557.
6.
Brown, M.D., B.J. Cornejo, T.B. Kuhn, J.R. Bamburg (2000) Cdc42 stimulates neurite outgrowth and formation of growth cone filopodia and lamellipodia. J Neurobiol 43: 352–364.
7.
Cajal, S.R.Y. (1890) À quelle époque apparaissent les expansions des cellules nerveuses de la moëlle épinière du poulet? Anat Anz 21–22: 609–639.
8.
Cheng, L., H. Jia., M. Löhr, A. Bagherzadeh, D.I.R. Holmes, D. Selwood, I. Zachary (2004) Anti-chemorepulsive effects of vascular endothelial growth factor and placental growth factor-2 in dorsal root ganglion neurons are mediated via neuropilin-1 and cyclooxygenase-derived prostanoid production. J Biol Chem 279: 30654–30661.
9.
Crawford, Y., N. Ferrara (2009) VEGF inhibition: insights from preclinical and clinical studies. Cell Tissue Res 335: 261–269.
10.
Dent, E.W., F.B. Gertler (2003) Cytoskeletal dynamics and transport in growth cone motility and axon guidance. Neuron 40: 209–227.
11.
Dickson, B.J. (2001) Rho GTPases in growth cone guidance. Curr Opin Neurobiol 11: 103–110.
12.
Ferrara, N. (2009) Vascular endothelial growth factor. Arterioscler Thromb Vasc Biol 29: 789–791.
13.
Ferrara, N., T. Davis-Smyth (1997) The biology of vascular endothelial growth factor. Endocr Rev 18: 4–25.
14.
Ferrara, N., H.P. Gerber, J. LeCouter (2003) The biology of VEGF and its receptors. Nat Med 9: 669–676.
15.
Grunwald, I.C., R. Klein (2002) Axon guidance: receptor complexes and signalling mechanisms. Curr Opin Neurobiol 12: 250–259.
16.
Gungabissoon, R.A., J.R. Bamburg (2003) Regulation of growth cone actin dynamics by ADF/cofilin. J Histochem Cytochem 51: 411–420.
17.
He, Z., M. Tessier-Lavigne (1997) Neuropilin is a receptor for the axonal chemorepellent semaphorin III. Cell 90: 739–751.
18.
Hofman, P., H.G.T. Blaauwgeers, M.J. Tolentino, A.P. Adamis, B.J. Nunes Cardozo, G.F.J.M Vrensen, R.O. Schlingemann (2000) VEGF-A induced hyperpermeability of blood-retinal barrier endothelium in vivo is predominantly associated with pinocytotic vesicular transport and not with formation of fenestrations. Curr Eye Res 21: 637–645.
19.
Holmes, D.I.R., I. Zachary (2005) The vascular endothelial growth factor (VEGF) family: angiogenic factors in health and disease. Genome Biol 6: 209.
20.
Hou, S.T., S.X. Jiang, R.A. Smith (2008) Permissive and repulsive cues and signalling pathways of axonal outgrowth and regeneration. Int Rev Cell Mol Biol 267: 125–181.
21.
Huber, A.B., A.L. Kolodkin, D.D. Ginty, J.F. Cloutier (2003) Signalling at the growth cone: ligand-receptor complexes and the control of axon growth and guidance. Ann Rev Neurosci 26: 509–563.
22.
Hurwitz, H., L. Fehrenbacher, W. Novotny, T. Cartwright, J. Hainsworth, W. Heim, J. Berlin, A. Baron, S. Griffing, E. Holmgren, N. Ferrara, G. Fyfe, B. Rogers, R. Ross, F. Kabbinavar (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335–2342.
23.
Jin, K., X.O. Mao, D.A. Greenberg (2004) Vascular endothelial growth factor stimulates neurite outgrowth from cerebral cortical neurons via Rho kinase signaling. J Neurobiol 66: 236–242.
24.
Kelly, R.J., O. Rixe (2009) Axitinib – a selective inhibitor of the vascular endothelial growth factor (VEGF) receptor. Target Oncol 4: 297–305
25.
Kunlin, J., X.O. Mao, D.A. Greenberg (2005) Vascular endothelial growth factor stimulates neurite outgrowth from cerebral cortical neurons via Rho kinase signaling. J Neurobiol 66: 236–242.
26.
Kutcher, M.E., M. Klagsbrun, R. Mamluk (2004) VEGF is required for the maintenance of dorsal root ganglia blood vessels but not neurons during development. FASEB J 18: 1952–1964.
27.
Lamalice, L., F. Houle, G. Jourdan, J. Hout (2004) Phosphorylation of tyrosine 1214 on VEGFR2 is required for VEGF-induced activation of Cdc42 upstream of SAPK2/ p38. Oncogene 23: 434–445.
28.
Madduri, S., B. Gander (2010) Schwann cell deliviery of neurotrophic factors for peripheral nerve regeneration. J Peripher Nerv Syst 15:93–103.
29.
Marko, S.B., D.H. Damon (2008) VEGF promotes vascular sympathetic innervation. Am J Physiol Heart Circ Physiol 294: 2646–2652
30.
Maskery, S., T. Shinbrot (2005) Deterministic and stochastic elements of axonal guidance. Ann Rev Biomed Eng 7: 187–221.
31.
Matsumoto, T., H. Mugishima (2006) Signal transduction via vascular endothelial growth factor (VEGF) receptors and their role in atherogenesis. J Atheroscler Thromb 13: 130–135.
32.
Meller, K. (1974) The reaggregation of neurons and their satellite cells in cultures of trypsin-dissociated spinal ganglia. Cell Tissue Res 152: 175–183.
33.
Meyer, G., E.L. Feldman (2002) Signaling mechanisms that regulate actin-based motility processes in the nervous system. J Neurochem 83: 490–503.
34.
Nakai, J. (1956) Dissociated dorsal root ganglia in tissue culture. Am J Anat 99: 81–129.
35.
Presta, L.G., H. Chen, S.J. O’Connor, Y. Chisholm, Y.G. Meng, L. Krummen, M. Winkler, N. Ferrara (1997) Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57: 4593–4599.
36.
Rosenstein, J.M., N. Mani, A. Khaibullina, J.M. Krum (2003) Neurotrophic effects of vascular endothelial growth factor on organotypic cortical explants and primary cortical neurons. J Neurosci 23: 11036–11044.
37.
Rousseau, S., F. Houle, J. Landry, J. Huot (1997) p38 MAP kinase activation by vascular endothelial growth factor mediates actin reorganization and cell migration in human endothelial cells. Oncogene 15: 2169–2177.
38.
Rousseau, S., F. Houle, J. Hout (2000a) Integrating the VEGF signals leading to actin-based motility in vascular endothelial cells. Trends Cardiovasc Med 10: 321–327.
39.
Rousseau, S., F. Houle, H. Kotanides, L. Witte, J. Waltenberger, J. Landry, J. Huot (2000b) Vascular endothelial growth factor (VEGF)-driven actin-based motility is mediated by VEGFR2 and requires concerted activation of stress-activated protein kinase 2 (SAPK2/p38) and geldanamycin-sensitive phosphorylation of focal adhesion kinase. J Biol Chem 275: 10661–10672.
40.
Samii, A., J. Unger, W. Lange (1999) Vascular endothelial growth factor expression in peripheral nerves and dorsal root ganglia in diabetic neuropathy in rats. Neurosci Lett 262: 159–162.
41.
Senger, D.R., S.J. Galli, A.M. Dvorak, C.A. Perruzzi, V.S. Harvey, H.F. Dvorak (1983) Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219: 983–985.
42.
Sondell, M., G. Lundborg, M. Kanje (1999) Vascular endothelial growth factor has neurotrophic activity and stimulates axonal outgrowth, enhancing cell survival and Schwann cell proliferation in the peripheral nervous system. J Neurosci 19: 5731–5740.
43.
Sondell, M., F. Sundler, M. Kanje (2000) Vascular endothelial growth factor is a neurotrophic factor which stimulates axonal outgrowth through the flk-1 receptor. Eur J Neurosci 12: 4243–4254.
44.
Takahashi, T., M Shibuya (1997) The 230kDa mature form of KDR/Flk-1 (VEGF receptor-2) activates the PLC-y pathway and partially induces mitotic signals in NIH3T3 fibroblasts. Oncogene 14: 2079–2089.
45.
Theiss, C., K. Meller (2002) Microinjected anti-actin antibodies decrease gap junctional communication in cultures astrocytes. Exp Cell Res 281: 197–204.
46.
Theiss, C., A. Mazur, K. Meller, H.G. Mannherz (2007) Changes in gap junction organisation and decreased coupling during induced apoptosis in lens epithelial cells. Exp Cell Res 313: 38–52.
47.
Vaisman, N., D. Gospodarowicz, G. Neufeld (1990) Characterization of the receptors for vascular endothelial growth factor. J Biol Chem 265: 19461–19466.
48.
Van Troys, M., L. Huyck, S. Leyman, S. Dhaese, J. Vandekerkhove, C. Ampe (2008) Ins and outs of ADF/cofilin activity and regulation. Eur J Cell Biol 87: 649–667.
49.
Zachary, I. (2005) Neuroprotective role of vascular endothelial growth factor: Signalling mechanisms, biological function, and therapeutic potential. Neurosignals 14: 207–221.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.